Cabergoline serves as a highly selective, long-acting dopamine D2 receptor agonist designed to suppress prolactin secretion and restore physiological endocrine balance in patients with hyperprolactinemic conditions. This formulation leverages a precise synergy between the active pharmaceutical ingredient and optimized excipients to maintain molecular stability and ensure a sustained therapeutic effect with minimal dosing frequency. The capsule delivery system provides a distinct clinical advantage by facilitating rapid disintegration and uniform drug release, which enhances gastrointestinal tolerability and maximizes systemic bioavailability for superior patient compliance.

Reviews
There are no reviews yet.